Characterization of breakthrough hemolysis events observed in the phase 3 randomized studies of ravulizumab versus eculizumab in adults with paroxysmal nocturnal hemoglobinuria.
Haematologica
; 106(1): 230-237, 2021 01 01.
Article
in En
| MEDLINE
| ID: mdl-31949012
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Hemoglobinuria, Paroxysmal
Type of study:
Clinical_trials
Limits:
Adult
/
Humans
Language:
En
Journal:
Haematologica
Year:
2021
Type:
Article
Affiliation country:
United States